{"id":"NCT01802411","sponsor":"Pacira Pharmaceuticals, Inc","briefTitle":"Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2013-03-01","resultsPosted":"2020-12-09","lastUpdate":"2021-07-12"},"enrollment":191,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Posterolateral Thoracotomy","Postoperative Pain"],"interventions":[{"type":"DRUG","name":"EXPAREL 266 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"EXPAREL 266 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.","primaryOutcome":{"measure":"Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours","timeFrame":"0-72 hours postsurgery","effectByArm":[{"arm":"EXPAREL 266 mg","deltaMin":472.1,"sd":37.19},{"arm":"Placebo","deltaMin":459,"sd":36.57}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5598"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":21,"countries":["United States","Bulgaria","Czechia","Georgia","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":94},"commonTop":["Pyrexia","Vomiting","Nausea","Hypertension","Fatigue"]}}